Opinion|Podcasts|January 14, 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Author(s)Wayne Kuang, MD, Steven Maislos, MD

Listen

0:00 / 0:00

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

54:53-58:54 OAB Comobidities

58:49-1:06:13 OAB Care

1:06:14-1:10:48 Innovations in OAB Management

1:10:49-1:14:08 Shared Decision-Making in OAB

1:14:09-1:21:40 Implications of Untreated OAB

1:21:41-1:29:44 OAB Treatment Medical Landscape

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related to this article

October 22nd, 2026

Engy Habashy, MD, on the role of androgens in GSM management

Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.

October 22nd, 2026

How PSMA-PET shapes staging and recurrence workup in prostate cancer

Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.

October 21st, 2026

Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC

Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.

October 21st, 2026

Q&A: Jeffrey Spier, MD, on ARPI fatigue and the case for dose reduction

Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.

October 21st, 2026

European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC

This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.

October 20th, 2026

ESMO 2026: Key presentations across genitourinary oncology

Take a look through some of the notable data presentations at this year's ESMO Congress.

October 20th, 2026

Casdatifan shows activity across treatment settings in advanced ccRCC

The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.